Urology News and Research

Latest Urology News and Research

Oxford Gene Technology launches Cytocell FISH probe for bladder cancer

Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched its CE-IVD labelled Cytocell Aquarius® P16/3c/7c/17c Probe Kit, a cost-effective, ready-to-use fluorescence in situ hybridisation (FISH) probe kit for non-invasive detection of bladder cancer — for sale in Europe.

From Oxford Gene Technology 6 Oct 2015

Mycobacterium could be more effective in treating superficial bladder cancer, study finds

Universitat Autònoma de Barcelona researchers have found a mycobacterium that is more effective in treating superficial bladder cancer and does not cause infections, unlike those used up to now.

6 Oct 2015

Testosterone therapy not associated with increased risk of aggressive prostate cancer: Study

A new population-based study from The University of Texas Medical Branch at Galveston showed for the first time that exposure to testosterone therapy over a five-year period was not associated with an increased risk of aggressive prostate cancer. Further, risk of high-grade prostate cancer did not increase according to the total number of testosterone injections.

5 Oct 2015

Allergan receives FDA approval to market JUVEDERM ULTRA XC for use in lips

Allergan plc, a leading global pharmaceutical company, today announced that the company has received approval from the U.S. Food and Drug Administration to market JUVEDERM ULTRA XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21. JUVEDERM ULTRA XC instantly adds fullness to the lips and is the only dermal filler that has proven results lasting up to one year for lip augmentation.

1 Oct 2015

Experimental drug shows promise in mice with multiple sclerosis

An experimental drug originally identified in a National Cancer Institute library of chemical compounds as a potential therapy for brain and basal cell cancers improves the symptoms of mice with a form of the debilitating neurological disorder multiple sclerosis (MS), according to new research from NYU Langone Medical Center.

1 Oct 2015

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).

30 Sep 2015

OncoGenex meets target enrollment in apatorsen Phase 2 trial

OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.

30 Sep 2015

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

An international team of cancer researchers that included UT Southwestern Medical Center physicians announced "game-changing results" using the immunotherapy drug nivolumab to treat certain lung cancers that failed to respond to first-line therapies.

29 Sep 2015

Phase II IMvigor 210 data shows atezolizumab may prevent progression of metastatic urothelial bladder cancer

Data presented today at the 2015 European Cancer Congress (ECC) demonstrates that the investigational immunotherapy atezolizumab may prevent progression of metastatic urothelial bladder cancer (mUBC) in all age groups by 2.1 months.

29 Sep 2015

New global educational initiative helps men identify symptoms of advanced prostate cancer

Although prostate cancer may exhibit no symptoms in its early stages, symptoms like severe or unexplained pain, difficulty walking or climbing stairs, difficulty sleeping or loss of bladder control may emerge when the disease advances as a signal to men to take action with their doctors.

29 Sep 2015

New global educational initiative helps men identify symptoms of advanced prostate cancer

29 Sep 2015

Fewer, higher doses of radiotherapy effective at treating prostate cancer

Giving fewer but higher doses of radiotherapy, is as effective at treating prostate cancer as giving lower doses for a longer period, according to new research* presented at the 2015 European Cancer Congress today (Monday).

28 Sep 2015

Keck School of Medicine of USC researcher wins first Hearst Fellowship

Albert D. Kim, Ph.D., a postdoctoral fellow at the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at the University of Southern California, is the first Keck School of Medicine of USC researcher to win a Hearst Fellowship for his work investigating how to turn stem cells into nephrons, the functional units of the kidney.

26 Sep 2015

TIS physicians selected as recipients of D Magazine 2015 Best Doctors in Dallas

More than 30 physicians credentialed to practice at Texas Institute for Surgery at Texas Heath Presbyterian Dallas (TIS) are recognized by D Magazine in its October issue, Best Doctors 2015.

26 Sep 2015

Allergan releases generic INVEGA (paliperidone extended-release tablets) in the U.S.

Allergan plc, a leading global pharmaceutical company, today announced that it has launched a generic version of Janssen's INVEGA (paliperidone extended-release tablets) in the U.S. Allergan is the first company to receive FDA approval for and launch a generic version of INVEGA, demonstrating the deep expertise of the Company's global generics R&D, regulatory and supply chain teams.

25 Sep 2015

JRC, CERN to explore potential of accelerator-driven method for producing targeted alpha therapy for cancer

A novel, accelerator-driven method could produce nuclides for targeted alpha therapy of cancer in practically unlimited amounts, overcoming current obstacles for its wider use due to a limited production of alpha-emitters. The JRC and the Conseil Européen pour la Recherche Nucléaire have embarked to explore the potential of the jointly proposed method.

24 Sep 2015

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.

23 Sep 2015

Prashant Mahajan awarded $5.76 million grant to study how febrile infants can avoid invasive procedures

Prashant Mahajan, M.D., professor of Pediatrics and Emergency Medicine, chief of the Division of Emergency Medicine in the Department of Pediatrics at Wayne State University and Children's Hospital of Michigan, has been awarded a five-year, $5.76 million grant (1R01HD085233) by the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health.

23 Sep 2015

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced that the U.S. Food and Drug Administration approved LONSURF (trifluridine and tipiracil), formerly known as TAS-102, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

22 Sep 2015

Family history: The most vital risk factor for prostate cancer

Family history is the most critical risk factor for prostate cancer. Men are more at risk if they had a father or brother with prostate cancer.

22 Sep 2015

Urology News and Research

Latest Urology News and Research

Oxford Gene Technology launches Cytocell FISH probe for bladder cancer

Mycobacterium could be more effective in treating superficial bladder cancer, study finds

Testosterone therapy not associated with increased risk of aggressive prostate cancer: Study

Allergan receives FDA approval to market JUVEDERM ULTRA XC for use in lips

Experimental drug shows promise in mice with multiple sclerosis

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

OncoGenex meets target enrollment in apatorsen Phase 2 trial

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

Phase II IMvigor 210 data shows atezolizumab may prevent progression of metastatic urothelial bladder cancer

New global educational initiative helps men identify symptoms of advanced prostate cancer

New global educational initiative helps men identify symptoms of advanced prostate cancer

Fewer, higher doses of radiotherapy effective at treating prostate cancer

Keck School of Medicine of USC researcher wins first Hearst Fellowship

TIS physicians selected as recipients of D Magazine 2015 Best Doctors in Dallas

Allergan releases generic INVEGA (paliperidone extended-release tablets) in the U.S.

JRC, CERN to explore potential of accelerator-driven method for producing targeted alpha therapy for cancer

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

Prashant Mahajan awarded $5.76 million grant to study how febrile infants can avoid invasive procedures

FDA approves LONSURF for treatment of patients with metastatic colorectal cancer

Family history: The most vital risk factor for prostate cancer

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Urology News and Research

Latest Urology News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in